Enanta Pharmaceuticals (ENTA) Share-based Compensation (2012 - 2026)

Enanta Pharmaceuticals has reported Share-based Compensation for 15 years, with the latest figure at $3.7 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 20.05% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $15.8 million (down 32.87% YoY), and the FY2025 full-year result was $18.6 million, down 30.71% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.7 million, down from $3.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $8.1 million in Q4 2023, with the low at $3.7 million in Q1 2026.
• Historically, Share-based Compensation has averaged $6.0 million across 5 years, with a median of $6.5 million in 2022.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 38.87% — and 2025, when it sank 47.73%.
• Enanta Pharmaceuticals' Share-based Compensation stood at $7.1 million in 2022, then rose by 13.45% to $8.1 million in 2023, then plunged by 30.04% to $5.7 million in 2024, then plunged by 32.76% to $3.8 million in 2025, then retreated by 1.63% to $3.7 million in 2026.
• The last three Share-based Compensation figures came in at $3.7 million (Q1 2026), $3.8 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.